Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Overview | Financials
Company Name Aurinia Pharmaceuticals Inc.
Symbol AUPH
Currency USD
Price 8.34
Market Cap 1,192,544,940
Dividend Yield 0%
52-week-range 4.71 - 10.05
Industry Biotechnology
Sector Healthcare
CEO Mr. Peter S. Greenleaf M.B.A.
Website https://www.auriniapharma.com

An error occurred while fetching data.

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka

Related Stocks

BioCryst Pharmaceuticals, Inc. logo

BioCryst Pharmaceuticals, Inc.

BCRX

7.67 USD

SpringWorks Therapeutics, Inc. logo

SpringWorks Therapeutics, Inc.

SWTX

33.09 USD

Apollo Medical Holdings, Inc. logo

Apollo Medical Holdings, Inc.

AMEH

40.82 USD

Fulgent Genetics, Inc. logo

Fulgent Genetics, Inc.

FLGT

22.02 USD

Financials

Numbers are in millions USD

Numbers are in millions USD